<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl1" position="float"><object-id pub-id-type="doi">10.7554/eLife.09115.004</object-id><label>Table 1.</label><caption><p> Clinical and laboratory characteristics of the four patient cohorts.</p><p><bold>DOI:</bold><ext-link ext-link-type="doi" xlink:href="10.7554/eLife.09115.004">http://dx.doi.org/10.7554/eLife.09115.004</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="3">Value for cohort*</th><th/></tr><tr><th/><th>SRCV on ART</th><th>LTNP</th><th>Chronic ART</th><th>Recent SRCV</th></tr><tr><th/><th>n = 25</th><th>n = 17</th><th>n = 32</th><th>n = 10</th></tr></thead><tbody><tr><td><bold>Clinical characteristics</bold></td><td/><td colspan="1"/><td colspan="1"/><td colspan="1"/></tr><tr><td>Age (years)</td><td>44 (34&#8211;53)</td><td colspan="1">49 (31&#8211;51)</td><td colspan="1">48 (31&#8211;53)</td><td colspan="1">39 (30&#8211;46)</td></tr><tr><td>Number&#160;of&#160;females&#160;(%)</td><td>0 (0)</td><td>7 (41.2)</td><td>5 (15.6)</td><td>1 (10)</td></tr><tr><td>Total ART duration (years)</td><td>10.8 (4.2&#8211;11.9)</td><td colspan="">0</td><td colspan="">9.8 (4.9&#8211;14.7)</td><td colspan="">0</td></tr><tr><td>Viremia zenith (log<sub>10</sub>HIV-1 c/ml)</td><td>5.5 (2.4&#8211;5.9)</td><td colspan="">2.5 (1.6&#8211;2.8)</td><td colspan="">4.9 (1.9&#8211;5.5)</td><td colspan="">6.2 (5.2&#8211;6.4)</td></tr><tr><td>CD4 count, nadir (cells/mm<sup>3</sup>)</td><td>390 (107&#8211;466)</td><td colspan="">624 (507&#8211;693)</td><td colspan="">155 (0&#8211;266)</td><td colspan="">440 (284&#8211;495)</td></tr><tr><td>CD4 count at sampling (cells/mm<sup>3</sup>)</td><td>714 (476&#8211;977)</td><td colspan="">793 (414&#8211;1010)</td><td colspan="">624.5 (172&#8211;889)</td><td colspan="">440 (284&#8211;604)</td></tr><tr><td>CD4/CD8 ratio</td><td>1.10 (0.52&#8211;1.35)</td><td colspan="">0.91 (0.36&#8211;1.47)</td><td colspan="">0.74 (0.23&#8211;0.93)</td><td colspan="">0.62 (0.36&#8211;0.94)</td></tr><tr><td><bold>Virological markers</bold></td><td/><td colspan=""/><td colspan=""/><td colspan=""/></tr><tr><td>Total HIV-1 DNA (c/10<sup>6</sup>&#160;PBMCs)</td><td>92 (9.8&#8211;127.7)</td><td colspan="">48 (5.4&#8211;56.5)</td><td colspan="">137 (8.6&#8211;219.2)</td><td colspan="">1901.3 (602.4&#8211;4786.9)</td></tr><tr><td>Integrated HIV-1 DNA (c/10<sup>6</sup>&#160;PBMCs)</td><td>211.3 (0&#8211;589.3)</td><td colspan="">28.2 (0&#8211;158.4)</td><td colspan="">586.7 (131.6&#8211;918.2)</td><td colspan="">1802.7 (367.9&#8211;5890.6)</td></tr><tr><td>HIV-1 usRNA (c/10<sup>6</sup> PBMCs)</td><td>1.6 (0&#8211;3.7)</td><td colspan="">0.4 (0&#8211;3.51)</td><td colspan="">6.1 (0&#8211;10.1)</td><td colspan="">15.5 (0.9&#8211;100.6)</td></tr><tr><td>2-LTR circles (c/10<sup>6</sup>&#160;PBMCs)</td><td>2.1 (0&#8211;4.3)</td><td colspan="">0.8 (0&#8211;2.7)</td><td colspan="">1.3 (0&#8211;2.2)</td><td colspan="">13.3 (5.1&#8211;21.6)</td></tr><tr><td>Total HIV-1 DNA (c/10<sup>6</sup> cells)&#160;in rectal biopsies</td><td>27.2 (22.2&#8211;61.7)</td><td colspan="">21.3 (16.7&#8211;34.5)</td><td colspan="">35.1 (16&#8211;77.5)</td><td colspan=""/></tr></tbody></table><table-wrap-foot><fn><p>*Values are reported as median (IQR); c: copies; PBMCs: peripheral blood mononuclear cells; usRNA: unspliced RNA; ART: antiretroviral therapy; SRCV on ART: early treated seroconverters; LTNP: long-term non-progressors; Chronic ART: late treated patients during chronic HIV-1 infection; Recent SRCV: acute ART-na&#239;ve seroconverters; LTR: Long terminal repeat.</p></fn></table-wrap-foot></table-wrap>